Clinical Trials List
Protocol NumberDS8201-801
NCT Number(ClinicalTrials.gov Identfier)NCT07015697
Not yet recruiting
2025-06-30 - 2028-12-31
Phase I
Recruiting5
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
-
Trial Applicant
Daiichi Sankyo Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/10
Investigators and Locations
Co-Principal Investigator
- MING-YANG WANG Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- 李佳真 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
- 魏以宣 Division of Ophthalmology
- 楊明翰 Division of Hematology & Oncology
- 林柏翰 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈士哲 Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- Chun-Hsiu Liu Division of Ophthalmology
- 阮昱翔 Division of Radiology
- Wen-Chi Shen Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
- Yung-Chang Lin Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Chung Wu Division of General Surgery
- 黃至豪 Division of General Surgery
- Chih-Jung Chen Division of General Surgery
- Chen-Teng Wu Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- 蘇孟夏 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Wei-Pang Chung
Co-Principal Investigator
- Shang-Hung Chen Division of Hematology & Oncology
- Kuo-Ting Lee Division of General Surgery
- 魏慈慧 Division of General Surgery
- Zhu-Jun Loh Division of General Surgery
- Jui-Hung Tsai Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
- 黃怡菁 Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Recurrent or Metastatic Solid Tumors
Objectives
This is a dose escalation and dose expansion study of subcutaneous trastuzumab deruxtecan (T-DXd) plus hyaluronidase, designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of subcutaneous T-DXd plus hyaluronidase in subjects with metastatic solid tumors.
Test Drug
Frozen crystal powder and liquid for injection
Active Ingredient
DS-8201a plus hyaluronidase
Dosage Form
24B
Dosage
subcutaneous T-DXd 300 mg; ALT-BB4 1500 IU/mL
Endpoints
1. Number of subjects experiencing treatment-induced adverse events (TEAEs)
TEAEs are defined as adverse events (AEs) that occur or worsen during treatment, specifically those occurring or worsening between the date of the first administration of the trial treatment and day 21 after the last administration of the trial treatment.
2. Area under the plasma concentration-time curve
3. Number of subjects experiencing dose-limiting toxicities (DLTs) during the dose escalation phase
TEAEs are defined as adverse events (AEs) that occur or worsen during treatment, specifically those occurring or worsening between the date of the first administration of the trial treatment and day 21 after the last administration of the trial treatment.
2. Area under the plasma concentration-time curve
3. Number of subjects experiencing dose-limiting toxicities (DLTs) during the dose escalation phase
Inclution Criteria
Key Inclusion Criteria:
Sign and date the ICF, prior to the start of any trial- specific qualification procedures.
Adults ≥18 years or the minimum legal adult age (whichever is greater).
a) Disease State: If HER2 status is required for eligibility (for all populations, except "Pan-tumor, heavily pretreated, with no SoC"), a documented HER2 test result must be available. A participant population would only be considered in regions where T-DXd is approved for that indication and an approved or validated test is available, if required per country regulations. Note: for all indications, all local HR testing and HER2 testing shall be per ASCO/CAP guidelines, as applicable, in the advanced setting, using a validated or approved test as required per local regulations. The most recent available samples should be used to confirm eligibility, if applicable. For full description of each population, see below. Breast Cancer: adults with pathologically documented unresectable or metastatic breast cancer HER2-positive BC: have received a prior anti-HER2-based regimen. For HER2-positive BC participants in Part 2 only, prior anti-HER2 based therapy should have been received in either:
the metastatic setting, or
the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. HR-, HER2-low BC: have received a prior systemic cytotoxic therapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing (neo)adjuvant chemotherapy. HR+, HER2-low/ultralow BC: have received previous ET AND an additional line of ET must not be the next line of treatment considered in the participant's best interest.
For participants in Part 2 with HR+ HER-2low/ultralow BC, the following criteria also apply:
had disease progression while receiving 1 previous line of ET with a CDK4/6i and is not expected to benefit from immediate use of a second line of ET, OR
had disease progression on at least 2 previous lines of ET with or without a target therapy such as CDK4/6, mTOR or PI3-K inhibitors) administered for the treatment of metastatic disease
of note:
If the 1 line was given while in the adjuvant setting, if disease recurrence occurred while on the first 24 months of adjuvant ET, that will be considered a line of therapy and only 1 additional line of ET will be required in the metastatic setting, with or without targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors)
Any progression after discontinuing or completing a course of adjuvant ET will not be considered a line of therapy
Single agent PARP inhibitor therapy does not count as ET or as cytotoxic is not considered a line of ET
Changes in dosing schedules, or discontinuations/restarting of the same drugs or the addition of a targeted therapy to an ET without progression (eg, adding a CDK4/6 inhibitor to a current aromatase inhibitor regimen) will not be considered separate lines of therapy.
participants may not have received more than 2 prior lines of cytotoxic therapy in the recurrent or metastatic setting. NSCLC, HER2 mut: adults with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy.
Gastric Cancer, HER2-positive: adults with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction adenocarcinoma who have received a prior anti-HER2-based regimen Pan-tumor, HER2-positive: adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior treatment or have no satisfactory alternative treatment options Heavily pretreated tumors: adults with unresectable or metastatic solid tumors (other than described above), who have received prior systemic treatment and have no satisfactory treatment alternative b) Part 2 only: At least 1 RECIST 1.1 measurable lesion on CT or MRI.
Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting trial intervention.
Part 2 only: confirmation of availability of the most recent available adequate FFPE archival tumor tissue sample obtained in the advanced setting, or provision of newly obtained tumor tissue if clinically feasible and at an acceptable risk as determined by the Investigator.
ECOG PS of 0 to 1.
Sign and date the ICF, prior to the start of any trial- specific qualification procedures.
Adults ≥18 years or the minimum legal adult age (whichever is greater).
a) Disease State: If HER2 status is required for eligibility (for all populations, except "Pan-tumor, heavily pretreated, with no SoC"), a documented HER2 test result must be available. A participant population would only be considered in regions where T-DXd is approved for that indication and an approved or validated test is available, if required per country regulations. Note: for all indications, all local HR testing and HER2 testing shall be per ASCO/CAP guidelines, as applicable, in the advanced setting, using a validated or approved test as required per local regulations. The most recent available samples should be used to confirm eligibility, if applicable. For full description of each population, see below. Breast Cancer: adults with pathologically documented unresectable or metastatic breast cancer HER2-positive BC: have received a prior anti-HER2-based regimen. For HER2-positive BC participants in Part 2 only, prior anti-HER2 based therapy should have been received in either:
the metastatic setting, or
the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. HR-, HER2-low BC: have received a prior systemic cytotoxic therapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing (neo)adjuvant chemotherapy. HR+, HER2-low/ultralow BC: have received previous ET AND an additional line of ET must not be the next line of treatment considered in the participant's best interest.
For participants in Part 2 with HR+ HER-2low/ultralow BC, the following criteria also apply:
had disease progression while receiving 1 previous line of ET with a CDK4/6i and is not expected to benefit from immediate use of a second line of ET, OR
had disease progression on at least 2 previous lines of ET with or without a target therapy such as CDK4/6, mTOR or PI3-K inhibitors) administered for the treatment of metastatic disease
of note:
If the 1 line was given while in the adjuvant setting, if disease recurrence occurred while on the first 24 months of adjuvant ET, that will be considered a line of therapy and only 1 additional line of ET will be required in the metastatic setting, with or without targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors)
Any progression after discontinuing or completing a course of adjuvant ET will not be considered a line of therapy
Single agent PARP inhibitor therapy does not count as ET or as cytotoxic is not considered a line of ET
Changes in dosing schedules, or discontinuations/restarting of the same drugs or the addition of a targeted therapy to an ET without progression (eg, adding a CDK4/6 inhibitor to a current aromatase inhibitor regimen) will not be considered separate lines of therapy.
participants may not have received more than 2 prior lines of cytotoxic therapy in the recurrent or metastatic setting. NSCLC, HER2 mut: adults with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy.
Gastric Cancer, HER2-positive: adults with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction adenocarcinoma who have received a prior anti-HER2-based regimen Pan-tumor, HER2-positive: adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior treatment or have no satisfactory alternative treatment options Heavily pretreated tumors: adults with unresectable or metastatic solid tumors (other than described above), who have received prior systemic treatment and have no satisfactory treatment alternative b) Part 2 only: At least 1 RECIST 1.1 measurable lesion on CT or MRI.
Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting trial intervention.
Part 2 only: confirmation of availability of the most recent available adequate FFPE archival tumor tissue sample obtained in the advanced setting, or provision of newly obtained tumor tissue if clinically feasible and at an acceptable risk as determined by the Investigator.
ECOG PS of 0 to 1.
Exclusion Criteria
Key Exclusion Criteria:
Prior treatment with ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor; NOTE exception for SDC 1 and 2, where prior exposure to such agents is permitted provided the following are met:
At least 1 year has elapsed since last dose of exatecan derivative ADC.
The participant did not discontinue nor reduce the dose due to toxicity.
The participant did not experience any drug-related Grade 3/4 toxicity.
The participant did not experience ILD of any grade while on or after the exatecan derivative ADC treatment.
Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products.
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
Medical history of MI within 6 months before enrollment or symptomatic CHF (New York Heart Association class II to IV). Participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI-related symptoms should have a cardiologic consultation during the Screening Period to rule out MI.
Has a corrected QT interval (QTcF) prolongation to > 480 ms (regardless of participant's sex) based on average of the screening triplicate 12-lead ECG.
Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Prior treatment with ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor; NOTE exception for SDC 1 and 2, where prior exposure to such agents is permitted provided the following are met:
At least 1 year has elapsed since last dose of exatecan derivative ADC.
The participant did not discontinue nor reduce the dose due to toxicity.
The participant did not experience any drug-related Grade 3/4 toxicity.
The participant did not experience ILD of any grade while on or after the exatecan derivative ADC treatment.
Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug products.
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
Medical history of MI within 6 months before enrollment or symptomatic CHF (New York Heart Association class II to IV). Participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI-related symptoms should have a cardiologic consultation during the Screening Period to rule out MI.
Has a corrected QT interval (QTcF) prolongation to > 480 ms (regardless of participant's sex) based on average of the screening triplicate 12-lead ECG.
Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
76 participants
